We studied the effects of PTH on the expression of tumor necrosis factor-related activation-induced cytokine (TRANCE), osteoprotegerin (OPG), and receptor activator of NF B (RANK) messenger RNA (mRNA) in cultured murine bone marrow, calvaria, and osteoblasts. TRANCE, OPG, and RANK are recently identified regulators of osteoclast formation. Bone marrow cells were cultured with or without PTH(1-34) for 6 days. TRANCE, OPG, and RANK mRNA were measured by RT-PCR. In 6-day cultures, PTH stimulated the number of OCL/well in a dose-dependent manner. A time course showed significant (P Ͻ 0.01) increases in OCL/well after 24 h of PTH (100 ng/ml). TRANCE mRNA expression, like OCL formation, increased dose dependently and was maximal, with 10 -100 ng/ml PTH. In contrast, OPG mRNA expression was decreased by 0.1 ng/ml PTH (40%) and completely abolished by 1 ng/ml. TRANCE mRNA expression was rapidly stimulated by PTH (maximal response at 1 h, 8.1-fold over control). Expression declined by 40% at 24 h but was still much greater than control at 6 days (4.6-fold) in a time-course study. PTH caused a transient stimulation of OPG mRNA at 1 h (2-fold), which returned to basal levels by 2 h. After 6 h, PTH completely inhibited OPG mRNA. There were only minor effects of PTH on RANK mRNA expression. PTH had less potent effects on TRANCE and OPG mRNA expression in calvaria organ cultures and osteoblasts. In mouse calvaria cultures, TRANCE expression was detectable in controls and was increased 2.9-fold by PTH at 24 h. PTH treatment of calvaria decreased OPG expression by 30% at 6 h. MC3T3 E-1 osteoblastic cells expressed minimal levels of TRANCE mRNA either before or after PTH treatment. OPG mRNA was present in MC3T3 E-1 cells, but levels were not modulated by PTH. In primary osteoblastic cells, PTH stimulated TRANCE mRNA expression 4-fold at 2 h and inhibited OPG mRNA expression by 46%.
S
TEADY-STATE BONE mass represents the net balance of the rates of bone formation and resorption. In turn, these indices reflect the relative activity of osteoblasts and osteoclasts, respectively (1) . Osteoclasts are multinucleated giant cells that originate from hematopoietic stem cells of the macrophage/monocyte lineage. They have distinct characteristics that include expression of tartrate-resistant acid phosphatase (TRAP) activity, calcitonin (CT) receptors, and the ability to resorb bone (2, 3) . Multiple local factors and systemic hormones regulate osteoclast formation and differentiation (2, 3) .
TRANCE [tumor necrosis factor (TNF)-related activationinduced cytokine], which is also known as ODF (osteoclast differentiation factor), RANKL (receptor activator of NFkappaB ligand), and OPGL (osteoprotegerin ligand), is a new member of the TNF ligand family that is induced upon T cell receptor binding (4 -6) . TRANCE was cloned during a search for apoptosis-regulatory genes using a somatic cell genetic approach in T cell hybridomas (4) . TRANCE stimulates osteoclast differentiation and bone resorption (7, 8) . It induces osteoclast-like cell (OCL) formation in spleen cells that are cultured without osteoblasts or stromal cells but with M-CSF (macrophage colony stimulating factor) (9) . TRANCE acts directly on osteoclast progenitors (10) and induces OCL formation in human peripheral blood mononuclear cell cultures in vitro (11) . It also induces bone resorption via activation of mature osteoclasts and inhibition of osteoclast-apoptosis (7, 8, 12) . OPG, which is also known as osteoclastogenesis inhibitory factor (OCIF), is a soluble receptor for TRANCE (7, 13) . OPG inhibits osteoclastogenesis by interrupting cell-to-cell signaling between ST-2 cells and osteoclast progenitors (10) , and recombinant OPG blocks osteoclastogenesis in vitro by inhibiting the differentiation of osteoclasts (14, 15) . OPG is present as a heparin-binding secretory glycoprotein that forms both 60-kDa monomer and a membrane-bound 120-kDa homodimer (16 -18) . Human and mouse OPG genes have been cloned and characterized. OPG is a single-copy gene with 5 exons that spans 29 kb in humans (19) and mice (20) . OPG is also a receptor for TRAIL (TNF-related ligand), which blocks the antiosteoclastogenic activity of OPG (21) . OPG knockout mice develop severe osteoporosis and have increased osteoclastogenesis, marked bone loss, destruction of their growth plate, and lack trabecular bone in their long bones (22, 23) . Transgenic mice that overexpress OPG are osteopetrotic and lack osteoclasts (14) . OPG prevents bone loss in ovariectomized rats and increases bone mineral density and bone volume in normal rats (14) . Expression of OPG is down-regulated by PG E 2 treatment in human bone marrow cells (24) . In contrast, OPG is up-regulated by interleukin (IL)-1␣ in the human osteosarcoma cell line MG-63 and human osteoblast-like cells (25) and by TNF-␣ and -␤ in MG63 cells (26) .
RANK (receptor activator of NF B), also known as ODAR (osteoclast differentiation and activation receptor) (27) , is a new member of the TNF receptor family that was first identified in dendritic cells. It is a membrane-bound receptor for TRANCE/RANKL (6) . RANK directly mediates TRANCEinduced osteoclast differentiation and activation in osteoclast precursor cells (27) . IL-4 and TGF-␤ induced surface expression of RANK on either phytohemagglutinin (PHA)-or anti-CD-3-activated peripheral blood T lymphocytes (6) .
In this study, we investigated whether PTH regulated TRANCE, OPG, and RANK messenger RNA (mRNA) expression in mouse bone marrow cells, mouse calvarial cultures, the immortalized osteoblastic cell line MC3T3 E-1, and primary osteoblastic cells.
Materials and Methods

Cell and organ cultures
Mouse bone marrow cells from C57BL/6 mice (Charles River Laboratories, Inc., Wilmington, MA) were isolated by a modification of previously published methods (28 -33) . Animals were housed in the 125 I]-salmon CT (0.04 Ci, 100,000 cpm/ml) in the absence or presence of cold sCT (10 Ϫ7 m; Bachem California, Inc.) at room temperature for 2 h. Cells were then washed with PBS twice to remove nonspecific radioactivity and were fixed with 2.5% glutaraldehyde in PBS. Slides were dipped in LM-1 photographic emulsion (1:1 dilution with 1.7% glycerol; Amersham, Arlington Heights, IL) for autoradiography. Cells were then developed and stained with Giemsa.
For PCR amplification, cells were plated in 10-cm culture dishes, at 1 ϫ 10 6 cells/cm 2 , with 10 ml of medium/dish. Cultures were fed every third day, and total RNA was extracted from cells on day 6 or at the appropriate time point.
Mouse calvaria were removed from 2-to 3-day-old CD-1 mice and dissected free from adhering soft tissue, as previously described (34) . Calvaria were precultured overnight in DMEM with 5% HIFCS and stimulated with or without PTH (100 ng/ml) for up to 48 h.
Primary osteoblasts from neonatal calvaria of CD-1 mice (Charles River Farms) were produced by sequential digestion, as previously described (35), and MC3T3 E-1 cells were cultured in DMEM containing 10% HIFCS with or without PTH (100 ng/ml) for up to 2 h.
PCR amplification
Total RNA was extracted from the bone marrow cultures, osteoblastic cells, MC3T3 E-1, or calvaria organ cultures, by either the acid guanidine isothiocyanate extraction and cesium chloride ultracentrifugation method (36) or with Tri-reagent (Molecular Research Center, Inc., Cincinnati, OH). Total RNA was converted to complementary DNA (cDNA, Gaithersburg, MD) by reverse transcriptase (Superscript II, Life Technologies, Inc., Gaithersburg, MD) and ran-FIG. 2. mRNA expression of TRANCE, OPG, RANK, and ␤-actin (ACTIN) assessed by RT-PCR. Mouse bone marrow cells were cultured for 6 days with or without PTH (0.001-100 ng/ml). A, Photographs of the PCR analysis from a representative experiment. Numbers below each band represent the ratio of the optical density of the band, normalized to the optical density of ␤-actin. B, Mean optical density ratio values for TRANCE and OPG, normalized to ␤-actin of duplicate independent experiments, to document the consistency of the results. TRANCE, OPG, and RANK were amplified for 30 cycles. ␤-Actin was amplified for 27 cycles. ND, None detected. dom hexamer. Sonicated salmon sperm DNA was used as a carrier. The first-strand cDNA was extracted with phenol/chloroform, precipitated, resuspended in sterile water, and amplified by PCR.
PCR amplification was done using gene-specific PCR primers and Taq polymerase (Amplitaq, Perkin-Elmer Corp., Norwalk, CT). The PCR mixture (without enzyme) was overlaid with mineral oil and heated to 94 C for 5 min. During the last minute, Amplitaq was added (hot start) and amplification was allowed to proceed in a thermal cycler (PerkinElmer Corp.). The temperature cycling was as follows: denaturation at 94 C for 1 min, primer annealing at 65 C for 2 min, and extension at 72 C for 3 min for 10 cycles. In subsequent cycles, the primer annealing temperature was decreased stepwise (step-down method), by 5 C, every 5 cycles. After the last cycle, the mixture was incubated at 72 C for 7 min. To verify that amplifications were in the linear range of each PCR analysis, we performed PCR amplification for up to 36 cycles with each amplimer set using samples prepared from either control or PTH-treated cultures. For bone marrow studies, TRANCE was amplified from control cultures and cultures treated with PTH for 1 h, which is the time when TRANCE mRNA levels seemed to be maximal. For OPG, we used control bone marrow, because PTH treatment had a predominantly inhibitory effect. For RANK, we used mRNA from bone marrow cultures that were treated with PTH for 6 days. Specific amplimer sets were designed from published cDNA sequences: murine TRANCE (6) (antisense: 5ЈGGGAATTACAAAGTGCACCAG3Ј; sense: 5ЈGGTCGGG-CAATT CTGAATT3Ј), murine OPG (14) (antisense: 5ЈTCAAGTGCTT-GAGGGCATAC3Ј; sense: 5ЈTGGAGATCGAATTCTGCTTG3Ј), murine RANK (6) (antisense: 5ЈGTCTTCTGGAACCA TCTTCTCC3Ј; sense: 5ЈCACAGACAAATGCAAACCTTG3Ј), ␤-actin (37) (antisense: 5ЈCT-CTTTGATGTCACGCACGAT-TTC3Ј; sense: 5ЈGTGGGCCGCTCTAG-GCACCAA3Ј). The amplified samples were run in a 1.5-2.0% agarose gel (depending on the product size), stained with ethidium bromide, and photographed under UV illumination. Images were captured by a FOTO/Analyst Archiver Electronic Documentation system (Fotodyne, Inc., Hartland WI), and optical density was determined using a digital image processing and analysis program (Scion Image, Scion Corp., Frederick, MD).
The identities of the amplified PCR products were confirmed by direct sequencing using an automatic DNA sequencer (PE Applied Biosystems, Norwalk, CT).
Statistical analysis
Statistical analysis was performed by one-way ANOVA, and by the Bonferroni post hoc test when ANOVA demonstrated significant differences. All experiments were repeated at least twice, and representative experiments are shown. 
Results
OCL formation
PTH increased OCL formation in a dose-dependent manner in 6-day mouse bone marrow cultures ( Table 1 ). The effect was significant for PTH at 1 to 100 ng/ml. As shown in Table 2 , PTH (100 ng/ml) significantly (P Ͻ 0.01) increased OCL formation after 24 h, and this effect was maximal after 4 days. In these time-course experiments, PTH was added during the last period of culture. At all time points, unstimulated cultures contained less than 10 OCL/well.
Autoradiography of [ 125 I]-sCT binding in mouse bone marrow cells
125 I]-sCT binding, as assessed by autoradiographs (Fig. 1, A 
and B). Binding of [
125 I]-sCT was specific because there were only background levels of grains accumulated over MNCs and mononucleated cells in the presence of excess unlabeled sCT (10 Ϫ7 m) (Fig. 1, C and D) . In both control and PTH-treated cultures, at all times, greater than 98% of the MNC were positive for [
125 I]-sCT binding.
Regulation of TRANCE, OPG, and RANK mRNA expression in mouse bone marrow cultures
Murine TRANCE, OPG, and RANK mRNA expression was measured by RT-PCR in bone marrow cells that were cultured for 6 days with or without PTH. TRANCE mRNA expression increased dose dependently with PTH, was maximal at 10 -100 ng/ml (4.6-fold increase, Fig. 2) , and was highly correlated with increases in OCL numbers in Table 1 (r ϭ 0.87, P Յ 0.05). In contrast, OPG mRNA expression was decreased 40% by 0.1 ng/ml PTH and essentially abolished by concentrations of 1 ng/ml or higher. Expression of OPG mRNA was inversely correlated with increases in OCL numbers in Table 1 (r ϭ Ϫ0.88, P Յ 0.05). RANK mRNA expression was low in control cultures, and PTH had a slight biphasic effect in the dose response study shown in Fig. 2 , causing an approximately 50% inhibition at 0.001-0.1 ng/ml and no consistent effect at 100 ng/ml (Figs. 2 and 3) . In time-course studies, PTH stimulated TRANCE mRNA expression approximately 8.1-fold between 1 and 6 h (Fig. 3) . Expression declined from peak levels at 24 h but was still much greater than control at 6 days (4.6-fold). PTH also had a biphasic effect on OPG mRNA expression. It caused a transient stimulation of levels at 1 h (2-fold), which FIG. 4 . mRNA expression of TRANCE, OPG, and RANK assessed by RT-PCR. Data were obtained from control and PTH (100 ng/ml)-treated 6-day mouse bone marrow cultures and normalized to mouse ␤-actin mRNA. Four independent experiments were performed, and total RNA samples were reverse-transcribed independently. Values represent the mean Ϯ SEM. TRANCE, OPG, and RANK were amplified for 30 cycles. ␤-Actin was amplified for 27 cycles. *, Significant effect of PTH, P Յ 0.001. returned to basal values by 2 h. After 6 h, it completely inhibited OPG mRNA. There was little effect of PTH (100 ng/ml) on RANK mRNA expression at any time point. To investigate the consistency of PTH (100 ng/ml) effects on TRANCE, OPG, and RANK mRNA expression in 6-day cultures and to perform statistical analysis, results from four independent experiments were pooled (Fig. 4) . This analysis demonstrated that PTH stimulated TRANCE 4.4-fold, completely inhibited OPG, and had no effect on RANK mRNA expression.
In the experiments of Figs. 2-4 , TRANCE, OPG, and RANK were amplified by PCR for 30 cycles, whereas ␤-actin was amplified for 27 cycles. To verify that we measured TRANCE, OPG, RANK, and ␤-actin mRNA in the linear range of each PCR analysis, we performed PCR amplification for each primer set over a range of 18 -36 cycles (Fig.  5) . In these experiments, samples from either control or PTH-treated bone marrow cultures were used for TRANCE mRNA. Samples from control bone marrow cultures were used for OPG mRNA. Samples from PTHtreated bone marrow cultures were used for RANK mRNA, and a combination of control and PTH-treated bone marrow cultures was used for ␤-actin mRNA. For TRANCE, PCR amplification was linear between cycle numbers 27 and 36 for control cultures and between 24 and 36 cycles for PTH-treated cultures. For OPG and RANK, PCR amplification was linear between cycle numbers 27 and 36. For ␤-actin, PCR amplification was linear between 24 and 36 cycles. Hence, for all the data shown in Figs. 2-4 , measurement of TRANCE, OPG, RANK, and ␤-actin mRNA was performed in the midlinear range of PCR amplification.
Regulation of TRANCE, OPG, and RANK mRNA expression by PTH in cultured mouse neonatal calvaria
TRANCE, OPG, and RANK mRNA expression was also measured by RT-PCR in neonatal murine calvaria cultures that were treated with or without PTH for up to 48 h. In these cultures, levels of TRANCE mRNA were greater than in bone marrow. Therefore, we performed RT-PCR amplification of TRANCE mRNA for only 25 cycles, because we documented that this number of cycles produced midlinear amplification, using analysis similar to that of Fig.  5 (data not shown). As shown in Fig. 6 , the level of TRANCE mRNA expression was minimal in control cultures and increased 1.5-, 2.8-, and 2.9-fold at 1 h, 6 h, and 24 h, respectively, by PTH treatment. At 48 h, TRANCE levels had decreased 30%, compared with cultures treated for 24 h, but were still 2-fold greater than control. In contrast to the marrow cultures, PTH had only a small inhibitory effect on OPG mRNA expression at any time point (maximum inhibition of 30% at 6 h). Dose response studies (Fig. 7 ), performed at 6 h, demonstrated TRANCE mRNA expression to increase 2-, 3.9-, and 4.6-fold with 1, 10, and 100 ng/ml PTH, respectively. As with bone marrow cultures, there was little effect of PTH treatment on RANK mRNA expression in calvaria cultures.
Regulation of TRANCE, OPG, and RANK mRNA expression by PTH in MC3T3 E-1 and primary osteoblastic cells
To investigate which cells might produce TRANCE, OPG, and RANK expression in mouse calvarial cultures, the murine-immortalized osteoblastic MC3T3 E-1 cells and primary osteoblastic cell populations from mouse calvaria were treated with or without PTH for 1 or 2 h (Fig. 8) . MC3T3 E-1 cells expressed minimal levels of TRANCE mRNA, either in control cultures or after PTH treatment. In contrast, OPG mRNA expression was detected in control cultures of these cells. However, PTH did not affect OPG mRNA expression in MC3T3 E-1 cells. Primary osteoblastic cells expressed TRANCE mRNA in control cultures and PTH stimulated expression 2.2-fold and 4-fold at 1 and 2 h, respectively, in 25 cycle-PCR amplification. In addition, PTH decreased OPG mRNA levels by 30% at 1 h and 46% at 2 h in primary osteoblasts. RANK mRNA expression was not detectable in MC3T3 E-1 cells, and only minimal levels were seen in primary osteoblastic cells, which likely represents contamination of these cultures with osteoclast precursors or other hematopoietic cells.
Discussion
In the current study, we found tight correlations between the number of TRAP (ϩ) multinucleated cells (OCL) generated in mouse bone marrow cultures by PTH and the levels of TRANCE and OPG mRNA. PTH increased OCL formation, enhanced TRANCE mRNA levels, and inhibited OPG mRNA expression at concentrations as low as 1 ng/ml. TRANCE is a stimulator of osteoclast formation. It is also necessary for osteoblast-mediated osteoclast activation (8) , and it regulates osteoclast differentiation and activation in culture models that do not contain stromal cells, vitamin D, or glucocorticoids (7) . In contrast, OPG is an inhibitor of TRANCE that prevents its binding to receptors on osteoclast precursor cells (7) . The finding of reciprocal regulation of TRANCE and OPG mRNA by PTH in murine bone marrow cultures suggests that regulation of both TRANCE and OPG contributes to the effects of PTH on OCL formation. In support of this hypothesis, we found in other studies, that maximal concentrations of IL-1 induced significantly fewer OCL in murine bone marrow cultures than did PTH (data not shown). In these experiments, the effects of IL-1 and PTH on TRANCE mRNA expression were similar. However, PTH inhibited OPG mRNA levels, whereas IL-1 had no effect.
Further evidence for a link between the effects of PTH on OCL formation and its effects on TRANCE and OPG mRNA comes from time-course studies. PTH rapidly stimulated TRANCE mRNA (at 1 h) and inhibited OPG mRNA (at 6 h). In contrast, PTH increased OCL numbers in the marrow cultures only after 24 h of treatment. These findings suggest that regulation of TRANCE and OPG mRNA is an early step in the stimulation of OCL by PTH in bone marrow cultures. The effects of PTH on OCL formation in murine bone marrow cultures may also be regulated by changes in M-CSF expression, because this cytokine is necessary for osteoclast formation from precursor cells (38) , and PTH stimulates M-CSF expression in osteoblastic cells (39) .
It is unlikely that PTH stimulates OCL formation through effects on RANK mRNA expression, because we found only small inhibitory effects of PTH on RANK mRNA levels in murine marrow cultures and no effect of PTH on RANK mRNA in calvaria organ cultures or primary osteoblastic cells. However, it is also possible that an additional receptor on osteoclast precursor cells may bind TRANCE and mediate its effects on osteoclast formation.
Expression of TRANCE and OPG in the murine bone marrow cultures probably occurs in the stromal cell populations, because these cells are known to be critical for osteoclast formation, and they respond to stimulators of resorption (7, 14) . Interestingly, we found less regulation of OPG and TRANCE mRNA expression by PTH in primary mouse osteoblasts and murine calvaria cultures. Similar lower levels of TRANCE and OPG regulation, compared with bone marrow cultures, were demonstrated in primary osteoblast, in a recent report (40) . Our findings demonstrate that expression of TRANCE and OPG mRNA in bone marrow cultures is extremely sensitive to PTH. Hence, these results suggest that a major role of PTH in bone is to regulate expression of TRANCE and OPG in cells of the bone marrow cultures. Because we found different levels of TRANCE and OPG regulation by PTH in bone marrow cells, calvaria, and osteoblasts, it is likely that there are complex mechanisms influencing TRANCE and OPG mRNA expression in bone. It seems that the greatest regulation of these factors is in the less differentiated stromal elements of the bone marrow cells, because these are present in bone marrow populations to a much greater degree than in primary osteoblasts or organ cultures.
MC3T3 E-1 cells are reported to not support osteoclast differentiation from precursor cells (3) . Our data would suggest that a major reason for this is because they produce little TRANCE but do produce OPG in both the basal state and after PTH stimulation. Hence, these cells express the mRNA of an inhibitor of osteoclast formation without expressing significant amounts of a major stimulator, TRANCE.
Regulation of TRANCE and OPG are likely critical pathways through which many, and possibly all, stimulators of resorption generate an osteoclastic response. Therefore, it will be interesting to determine which mechanisms are involved in these responses. It is likely that multiple pathways are used and that regulation is complex and dependent on a number of factors, including the differentiation state of the cell types that are studied and the time after stimulation when they are examined.
